Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) traded at $4.73 at last check on Monday, Sep 14, making a downturn move of -2.07% on its previous day’s price.
Looking at the stock we see that its previous close was $4.83 and the beta (5Y monthly) reads 0 with the day’s price range being $4.6800 – 5.1300. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, STSA has a high of $36.1 and a low of $4.55. The company’s stock has gained about -79.34% over that past 30 days.
Satsuma has a market cap of $95.78 Million and is expected to release its quarterly earnings report on August 12, 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the STSA stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.69, with the EPS growth for the year raised at -$2.5 for 2020 and -$1.51 for next year. These figures represent -0.48% and at -0.4% growth in EPS for the two years respectively.
There have been 1 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the STSA stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of Hold. Long term indicators on average place the stock in the category of 50% Sell.
Based on estimates by 5 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 2 have rated the Satsuma Pharmaceuticals, Inc. (STSA) stock as a Hold, while 2 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas 1 suggests the stock as a Sell. The stock has an overall rating of Hold and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the STSA stock currently stands at 0, and the current price level is -78.24% off its SMA20 and -80.33% from its 50-day simple moving average. The RSI (14) is pointing at 12.88 while the volatility over the past week is 28.45% and drops to 11.06% over the past one month. The beta value is 0, while the average true range (ATR) is currently pointing at 2.46. The average price target for the stock over the next 12 months is $11.75, with the estimates having a low of $4 and a high of $35. These price ends are -15.43% and +639.96% off the current price level respectively, although investors could be excited at the prospect of a -15.43% if the STSA share price touches on the median price of $4.
Let’s briefly compare Satsuma (STSA) stock to its peers. We find that today’s price change of -2.07% and -72.01% over the past 12 months for STSA competes that of Amgen Inc (AMGN), which has seen its stock price rise 1.46% in the latest trading session and is +26.23% over the last one year. Another of its peers Bristol-Myers Squibb Company (BMY) has climbed 1.2% today, and is +20.78% up over the past year, while Gilead Sciences Inc (GILD) is also down -2.07% yet its price remains in the red at -72.01% over the same period. Amgen has a P/E ratio of 20.16 compared to Satsuma’s 0 and Bristol-Myers 0. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 1.27% and 1.18%, respectively, in early deals.
Coming back to Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), we note that the average 3-month trading volume was 2.04 Million, while that of the preceding 10-day period stands at 24.71 Million. Current shares outstanding are 17.41 Million.
According to data from Thomson Reuters, insiders hold 11.91% of the company’s shares while institutions hold 77.85%. The data shows that short shares as of August 30, 2020, stood at 280.74 Million at a short ratio of 4.31. This represents a 1.61% Short interest in Shares outstanding on August 30, 2020. Shares short rose in August from the previous month at 259.84 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -75.97% down in year-to-date price movement.